Conversely, it is conceivable that patients with less severe forms of SMA may express sufficient levels of SMN for appropriate development and that some degenerative pathways that subsequently occur could be quite different to those that are triggered by developmental defects in Type I SMA. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.